Volume 73, Issue 5, Pages (May 2018)

Slides:

Advertisements

Similar presentations

The PSA Era is not Over for Prostate Cancer

Advertisements

Volume 60, Issue 2, Pages (August 2011)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 2, Pages (August 2010)

Volume 70, Issue 1, Pages (July 2016)

Testosterone Therapy in Men With Prostate Cancer

David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono

European Urology Focus

Volume 70, Issue 6, Pages (December 2016)

Volume 69, Issue 5, Pages (May 2016)

Volume 56, Issue 6, Pages (December 2009)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Volume 60, Issue 2, Pages (August 2011)

Volume 67, Issue 4, Pages (April 2015)

Volume 68, Issue 4, Pages (October 2015)

Volume 49, Issue 2, Pages (February 2006)

Volume 53, Issue 5, Pages (May 2008)

Volume 69, Issue 1, Pages (January 2016)

Volume 69, Issue 5, Pages (May 2016)

Volume 51, Issue 4, Pages (April 2007)

Managing Nonmetastatic Castration-resistant Prostate Cancer

Volume 52, Issue 3, Pages (September 2007)

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration- resistant Prostate Cancer in the Era of Precision Oncology Philipp.

Volume 71, Issue 2, Pages (February 2017)

Volume 68, Issue 4, Pages (October 2015)

Volume 65, Issue 5, Pages (May 2014)

Volume 74, Issue 1, Pages (July 2018)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 65, Issue 1, Pages (January 2014)

Androgen Receptor Variants and Castration-resistant Prostate Cancer: Looking Back and Looking Forward Takuma Uo, Cynthia Sprenger European Urology

Volume 71, Issue 1, Pages 1-3 (January 2017)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 70, Issue 4, Pages (October 2016)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Prostate Cancer Detection: A View of the Future

Volume 70, Issue 5, Pages (November 2016)

Volume 66, Issue 3, Pages (September 2014)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 70, Issue 5, Pages (November 2016)

Volume 70, Issue 1, Pages (July 2016)

Volume 70, Issue 4, Pages (October 2016)

The PSA Era is not Over for Prostate Cancer

Volume 53, Issue 2, Pages (February 2008)

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Leonard S. Marks, Jiaoti Huang European Urology

Volume 72, Issue 1, Pages (July 2017)

Volume 66, Issue 2, Pages (August 2014)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 74, Issue 2, Pages (August 2018)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 75, Issue 1, Pages (January 2019)

Volume 71, Issue 6, Pages (June 2017)

DNA Repair in Prostate Cancer: Biology and Clinical Implications

Volume 67, Issue 6, Pages (June 2015)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Volume 70, Issue 6, Pages (December 2016)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Volume 74, Issue 3, Pages (September 2018)

Volume 70, Issue 1, Pages (July 2016)

Volume 71, Issue 4, Pages (April 2017)

Volume 75, Issue 3, Pages (March 2019)

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

European Urology Oncology

Volume 53, Issue 6, Pages (June 2008)

Manfred Wirth, Peter Iversen, David McLeod, William See

Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer Adam Sharp,

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 73, Issue 5, Pages 687-693 (May 2018) Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study Joaquin Mateo, Heather H. Cheng, Himisha Beltran, David Dolling, Wen Xu, Colin C. Pritchard, Helen Mossop, Pasquale Rescigno, Raquel Perez-Lopez, Verena Sailer, Michael Kolinsky, Ada Balasopoulou, Claudia Bertan, David M. Nanus, Scott T. Tagawa, Heather Thorne, Bruce Montgomery, Suzanne Carreira, Shahneen Sandhu, Mark A. Rubin, Peter S. Nelson, Johann S. de Bono European Urology Volume 73, Issue 5, Pages 687-693 (May 2018) DOI: 10.1016/j.eururo.2018.01.010 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Kaplan–Meier curves for survival from date of castration resistance and from initial diagnosis based on the presence of gDDRm and specifically for gBRCA2m carriers. CRPC=castration-resistant prostate cancer; gDDRm=germline DNA damage repair gene mutation; IQR=interquartile range. European Urology 2018 73, 687-693DOI: (10.1016/j.eururo.2018.01.010) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Kaplan–Meier curves for progression-free survival on docetaxel and first-line ARSI therapy based on the presence of any gDDRm. ARSI=androgen receptor signalling inhibitor; gDDRm=germline DNA damage repair gene mutation; IQR=interquartile range; PFS=progression-free survival. European Urology 2018 73, 687-693DOI: (10.1016/j.eururo.2018.01.010) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 3 Kaplan–Meier curves depicting survival from detection of castration resistance, with patients grouped by exposure to PARP inhibitors and/or platinum therapy for (A) gDDRm+ or (B) gDDRm– metastatic castration-resistant prostate cancers. Dashed lines indicate the 95%CI limits. CI=confidence interval; CRPC=castration-resistant prostate cancer; gDDR=germline DNA damage repair; gDDRm=germline DNA damage repair gene mutation; IQR=interquartile range; PARPi=PARP inhibitor. European Urology 2018 73, 687-693DOI: (10.1016/j.eururo.2018.01.010) Copyright © 2018 European Association of Urology Terms and Conditions